| JERSX | MGLCX | JERSX / MGLCX | |
| Total Expense Ratio | 1.16 | 1.94 | 60% |
| Annual Report Gross Expense Ratio | 1.16 | 1.95 | 59% |
| Fund Existence | 18 years | 11 years | - |
| Gain YTD | 3.763 | 2.349 | 160% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 1000 | 250% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 312M | 2.22B | 14% |
| Annual Yield % from dividends | 2.90 | 2.05 | 141% |
| Returns for 1 year | 15.29 | 6.92 | 221% |
| Returns for 3 years | 14.27 | 4.80 | 297% |
| Returns for 5 years | 8.40 | -1.19 | -708% |
| Returns for 10 years | 73.85 | 29.92 | 247% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MMMSX | 23.99 | 0.33 | +1.39% |
| Victory Integrity Small/Mid-Cap Value Mb | |||
| GEMCX | 26.45 | 0.21 | +0.80% |
| Goldman Sachs Emerging Markets Eq C | |||
| ASIRX | 12.66 | 0.10 | +0.80% |
| Alger Small Cap Growth Institutional R | |||
| JDCRX | 43.37 | 0.18 | +0.42% |
| Janus Henderson Forty R | |||
| FTDZX | 175.43 | -2.44 | -1.37% |
| Franklin Biotechnology Discovery Adv | |||